Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...
A federal judge officially approved drug maker Purdue Pharma’s latest deal to settle thousands of lawsuits...
This fall, multiple states including Maryland, Virginia, Tennessee and Wisconsin have reported outbreaks of hand, foot...
A single infusion of an experimental gene-editing drug appears safe and effective for cutting cholesterol, possibly...
